Occam Places Prominent Scientific Leader at High Profile Neuro Startup
In October 2024, Occam recruited Laurens Kruidenier, PhD, as CSO of Nilo Therapeutics, a New York City based biotech backed by a blue chip syndicate.
Laurens joins Nilo from Cellarity, a Flagship investment employing an algorithmic, target-agnostic approach to drug discovery, where he served as CSO.
His first CSO role came at Prometheus Biosciences, an immunology play that sold to Merck for ~$11BN in 2023. Laurens began his industrial career at GSK.
About Nilo Therapeutics
Co-founded by Charles Zuker, Ruslan Medzhitov, and Steve Liberles, Nilo Therapeutics is an NYC-based biotech founded on seminal research revealing the ability to regulate human immune response via activation of neural circuits. The company is developing a pipeline of therapeutics for autoimmune and inflammatory indications.
In late 2024, Nilo raised a $101M Series A from The Column Group, DCVC Bio and Lux Capital.
Occam Global is an international life science executive search and leadership advisory firm dedicated to building management teams for innovative companies in the biotech, techbio, life sciences, and venture capital sectors. Our firm’s unique strength lies in our seamless access to elite talent, proven expertise in aligning exceptional business and scientific leaders with optimal opportunities, and a steadfast dedication to creating meaningful industry impact, guided by elevated ethics and enlightened aggression. Trusted by entrepreneurs, investors, and corporations worldwide, Occam Global is recognized as the premier partner for executive search and recruitment in the life sciences. Our success is rooted in establishing trust, cultivating and valuing relationships, and committing to serve as forthright and good-humored partners in realizing extraordinary ambitions.